Unicycive Therapeutics regains compliance with Nasdaq minimum market value requirement

Unicycive Therapeutics, Inc.

Nasdaq confirmed compliance with Listing Rule 5550(b)(2) on Sept 24, 2024 after market value exceeded $35M for 10 consecutive days.
Market value was above $35M from Sept 10 to Sept 23, 2024, regaining compliance.
Company had previously received a non-compliance notice on July 11, 2024 for failing to meet the minimum market value.
Removes immediate risk of delisting from Nasdaq Capital Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.